Neelima MishraSurendra Kumar PrajapatiKamlesh KaitholiaRam Suresh BhartiBina SrivastavaSobhan PhookanAnupkumar R. AnvikarVas DevGagan Singh SonalAkshay Chandra DhariwalNicholas J. WhiteNeena ValechaNational Institute of Malaria Research IndiaMinistry of Health and Family WelfareMahidol UniversityNuffield Department of Clinical Medicine2018-11-232018-11-232015-05-01Antimicrobial Agents and Chemotherapy. Vol.59, No.5 (2015), 2548-255310986596006648042-s2.0-84931292116https://repository.li.mahidol.ac.th/handle/20.500.14594/36455Copyright © 2015, American Society for Microbiology. All Rights Reserved. Malaria treatment in Southeast Asia is threatened with the emergence of artemisinin-resistant Plasmodium falciparum. Genome association studies have strongly linked a locus on P. falciparum chromosome 13 to artemisinin resistance, and recently, mutations in the kelch13 propeller region (Pfk-13) were strongly linked to resistance. To date, this information has not been shown in Indian samples. Pfk-13 mutations were assessed in samples from efficacy studies of artemisinin combination treatments in India. Samples were PCR amplified and sequenced from codon 427 to 727. Out of 384 samples, nonsynonymous mutations in the propeller region were found in four patients from the northeastern states, but their presence did not correlate with ACT treatment failures. This is the first report of Pfk-13 point mutations from India. Further phenotyping and genotyping studies are required to assess the status of artemisinin resistance in this region.Mahidol UniversityMedicineArticleSCOPUS10.1128/AAC.04632-14